Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5), the biotechnology company focused on gene therapies for age-related diseases, confirmed it has successfully raised £800,000 through a share subscription intended to advance its scientific programmes and strengthen its negotiating position for potential licensing deals.

The company has issued shares at 1.9p each, with each share accompanied by a warrant to subscribe for one additional stock at the same price within two years of issue.

If all warrants are exercised in full, Genflow would raise a further £800,000.

Both chief executive Eric Leire and newly appointed chairman Gad Berdugo participated in the subscription.

The new shares are expected to be admitted to trading on or around 11 March 2026, at which point the company's total issued share capital will comprise 535,653,205 ordinary shares.

Leire said the financing would support continued execution across the company's development programs and provide sufficient cash runway to approach potential licensing negotiations from a capitalised position.